Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tranexamic acid
Drug ID BADD_D02261
Description Tranexamic acid is a synthetic derivative of [lysine] used as an antifibrinolytic in the treatment and prevention of major bleeding. It possesses a similar mechanism of action to [aminocaproic acid] but is approximately 10-fold more potent.[L31883] It was first patented in 1957[A230108] and received its initial US approval in 1986.[L31858]
Indications and Usage Dunn CJ, Goa KL: Tranexamic acid: a review of its use in surgery and other indications. Drugs. 1999 Jun;57(6):1005-32.
Marketing Status Prescription; Discontinued
ATC Code B02AA02
DrugBank ID DB00302
KEGG ID D01136
MeSH ID D014148
PubChem ID 5526
TTD Drug ID D05HXX
NDC Product Code 12079-2001; 71052-166; 42571-314; 51754-0108; 67457-197; 71335-1957; 69918-301; 60505-6169; 70860-400; 0591-3720; 63629-8838; 67850-041; 50090-5072; 0013-1114; 51552-0513; 38779-3211; 42571-189; 49452-7877; 67850-042; 81999-0001; 43066-008; 72485-107; 68382-891; 39822-1000; 55150-188; 72611-760; 50090-4530; 49452-7876; 12848-1004; 71335-1981; 70121-1398; 51662-1532; 65388-0156; 61990-0611; 63323-563; 65145-106; 23155-166; 38779-2794; 81284-611; 70771-1085; 73309-178; 57218-951; 63629-8599; 51927-0022; 63759-0038; 62991-3131; 69918-300; 17478-017; 0517-0960; 81284-612; 17478-018; 62559-265; 68083-160; 55566-2110; 23155-524
Synonyms Tranexamic Acid | AMCHA | trans-4-(Aminomethyl)cyclohexanecarboxylic Acid | t-AMCHA | AMCA | Anvitoff | Cyklokapron | Ugurol | KABI 2161 | Spotof | Transamin | Amchafibrin | Exacyl
Chemical Information
Molecular Formula C8H15NO2
CAS Registry Number 701-54-2
SMILES C1CC(CCC1CN)C(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cardiac failure02.05.01.0010.014288%
Cardiogenic shock24.06.02.006; 02.05.01.0030.021433%Not Available
Cardiomyopathy02.04.01.0010.014288%Not Available
Cardiovascular disorder02.01.01.001; 24.03.02.009--Not Available
Cerebral infarction17.08.01.004; 24.04.06.0020.057154%Not Available
Cerebral thrombosis24.01.04.003; 17.08.01.006--Not Available
Cerebrovascular accident24.03.05.001; 17.08.01.0070.064298%
Chest discomfort02.02.02.009; 22.02.08.001; 08.01.08.0190.028577%Not Available
Chest pain08.01.08.002; 22.02.08.003; 02.02.02.0110.042865%Not Available
Chromatopsia06.02.05.001--Not Available
Circulatory collapse24.06.02.0010.005591%Not Available
Colour blindness03.01.01.001; 06.02.09.001--Not Available
Concussion17.11.01.004; 12.01.10.0050.014288%Not Available
Confusional state19.13.01.001; 17.02.03.005--
Constipation07.02.02.001--
Coronary artery thrombosis24.01.05.002; 02.02.01.0070.014288%Not Available
Death08.04.01.001--
Dermatitis allergic23.03.04.003; 10.01.03.014--Not Available
Dermatitis atopic23.03.04.016; 10.01.04.004--Not Available
Diarrhoea07.02.01.001--
Discomfort08.01.08.003--Not Available
Disturbance in attention19.21.02.002; 17.03.03.0010.005591%
Dizziness02.01.02.004; 24.06.02.007; 17.02.05.003--
Drug abuse19.07.02.0100.007455%Not Available
Dyspepsia07.01.02.001--
Dysphagia07.01.06.003--
Dyspnoea22.02.01.004; 02.01.03.0020.100019%
Embolic stroke24.01.04.010; 17.08.01.0320.021433%Not Available
Embolism venous24.01.01.0030.003727%Not Available
Epilepsy17.12.03.0020.014288%Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 7 Pages